Attovia Therapeutics (NASDAQ:ATTO) Issues Quarterly Earnings Results

Attovia Therapeutics (NASDAQ:ATTO) posted its quarterly earnings results on Wednesday. The company reported ($4.88) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $0.45 million for the quarter.

Attovia Therapeutics Trading Up 4.6%

Attovia Therapeutics stock opened at $24.20 on Friday. Attovia Therapeutics has a twelve month low of $16.15 and a twelve month high of $26.07.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ATTO. Leerink Partners began coverage on Attovia Therapeutics in a report on Monday. They set an “outperform” rating and a $52.00 price target for the company. Citigroup began coverage on Attovia Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 target price for the company. Morgan Stanley began coverage on Attovia Therapeutics in a report on Monday. They set an “overweight” rating and a $39.00 target price on the stock. Lifesci Capital started coverage on Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a report on Monday. They set an “outperform” rating and a $45.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $42.20.

Attovia Therapeutics News Summary

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Attovia reported preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b results are expected in the fourth quarter of 2026, with a Phase 2 trial planned for the first quarter of 2027. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
• Positive Sentiment: LifeSci Capital initiated coverage with an Outperform recommendation, adding a favorable external view of Attovia’s pipeline and potential valuation. LifeSci Capital initiates coverage of Attovia Therapeutics
• Positive Sentiment: Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, potentially increasing institutional awareness and investor interest in ATTO. New analyst coverage from major firms
• Neutral Sentiment: Management will participate in upcoming investor conferences, providing opportunities to discuss ATTO-1310, the clinical pipeline and corporate strategy with investors. Attovia Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Second-quarter results showed a net loss of $4.88 per share and revenue of only $0.45 million, while increased clinical-trial activity is expanding expenses and losses. The company remains dependent on successful trial outcomes and future financing. Attovia’s Q2 Loss Expands With Increased Trials for ATTO-1310

Insider Buying and Selling

In other news, Director Colin Walsh acquired 500,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the acquisition, the director directly owned 3,020,632 shares in the company, valued at $51,350,744. This represents a 19.84% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Xi L.P. Frazier bought 588,235 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the acquisition, the insider directly owned 6,154,213 shares of the company’s stock, valued at approximately $104,621,621. This represents a 10.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 2,740,587 shares of company stock valued at $47,269,979 in the last ninety days. 0.99% of the stock is currently owned by company insiders.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.